Wire · opportunities
Verseon bets physics can take drug design beyond AI's training data
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 July 2026 · Fusion42 review
Verseon, a computational drug design firm founded in 2002, claims its physics-based platform can discover novel small-molecule drugs outside the chemical space explored by AI training data, including reversible anticoagulants with lower bleeding risk than current therapies like Eliquis and Xarelto.
This Wire brief tracks EternaFusion, and It sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building AI drug discovery, you're training on 150 years of human chemistry — a few grains of sand in a 10^33-compound universe. Verseon's physics-first approach finds drugs AI cannot see, and their anticoagulant just cleared European patents with dramatically lower bleeding than Eliquis or Xarelto. The commercial model has shifted: it's not about better search of known space, it's about designing in unknown space.
◆ Mentioned in this story
◆ Coverage
1 source · 22 Jul 2026
◆ Related on Wire
◆ Topics